



Press Release Uppsala, Sweden, 17 December 2003

Gyros and George Washington University step up collaboration

Gyros AB revealed today that its collaboration with George Washington University to evaluate and develop the recently launched Gyrolab Bioaffy™ is being stepped up, after a successful feasibility phase.

Gyrolab Bioaffy is a solution for protein quantification, based on Gyros technology platform, in which single or multiplex immunoassays are performed at nanoliter scale in CD microlaboratories. Dr. Benjamin Dickens, Associate Research Professor, George Washington University has been evaluating the performance of Gyrolab Bioaffy in comparison with conventional techniques, initially using mouse samples. "We routinely have to assay proteins in extremely small amounts of sample," explained Dr. Dickens, "Current technologies are not optimized for small volumes so the ability to work at nanoliter scale on Gyrolab Bioaffy can be a tremendous advantage. Preliminary data was very promising and assay development appears to be fast and straightforward, so we are extending the study to human samples and focusing on the potential to monitor multiple analytes in a single sample."

Maris Hartmanis, CEO at Gyros AB, explained, "Collaborations such as these give us an excellent opportunity to see our products used under realistic laboratory conditions. The work has progressed smoothly and both partners are happy to continue in order to gain even more data of high scientific quality." Hartmanis continued, "We are confident that our approach to miniaturization and integration of immunoassays will enable maximum information to be gained from minimum amounts of sample. To have this substantiated by independent scientists is of great value to us."

About Gyros AB

Gyros miniaturizes and integrates laboratory applications, enabling scientists to generate more information from less sample and to improve lab performance. Using our proprietary technology platform, we increase productivity by streamlining the many steps of conventional applications into single, nanoliter scale procedures. Optimal environments are created for each application.

A Gyrolab microlaboratory, in the form of a compact disk, can process hundreds of samples in parallel, under the control of Gyrolab Workstation. Our company will realize the full potential of the Gyros technology platform in the fields of drug discovery and diagnostics. Initial product offerings are focused towards the growing area of proteomics. Gyros has 75 employees working at its headquarters in Uppsala Science Park, Sweden and in sales offices in the USA and Europe.

For further information, visit www.gyros.com or contact:

Maris Hartmanis, President and CEO, Gyros AB

Tel: +46 (0)18 566 330

Mobile: +46 (0)70 562 8617

Email: maris.hartmanis@gyros.com

Per Sjöberg, Executive Vice President Marketing and Sales, Gyros AB

Tel: +46 (0)18 566 318

Mobile: +46 (0)70 544 4799

Email: per.sjoberg@gyros.com

Björn Bontin, CFO and Investor Relations Manager

Tel: +46 (0)18 566521

Mobile: +46 (0)70 2480925

Email: bjorn.bontin@gyros.com

Sue Cresswell, Marketing Communications

Tel: +46 (0)8 54472620

Mobile: +46 (0)70 551 9520

Email: sue.cresswell@gyros.com

About George Washington University

The George Washington University Medical Center (GWUMC) is an internationally recognized, interdisciplinary academic health care center comprising the School of Medicine and Health Sciences; School of Public Health and Health Services; GW Hospital, which is jointly operated by Universal Health Services, Inc. (UHS); and GW Medical Faculty Associates, Inc. (MFA) which includes both the primary care and specialty practices of the medical faculty. GWUMC also has a longstanding tradition in research, with about 400 research projects currently underway. GWUMC is especially known for its Cancer Institute (GWCI), Response to Emergencies and Disasters Institute (READI), Institute for Spirituality and Health (GWISH), Ronald Reagan Institute for Emergency Medicine (RRIEM), Center for Health Policy, minimally invasive surgery, and cardiovascular research and treatment.

For further information, visit www.gwumc.edu

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.

Gyros, Gyrolab and the Gyros logo are registered trademarks of Gyros AB.